Paper · 42682425
Increased serum fibroblast growth factor 2 levels, altered peripheral blood inflammatory indicators and their ratios in amyotrophic lateral sclerosis: a clinical exploratory study.
Niu X and 5 others. Front Neurol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Increased serum fibroblast growth factor 2 levels, altered peripheral blood inflammatory indicators and their ratios in amyotrophic lateral sclerosis: a clinical exploratory study. Papers, record 42682425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42682425
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Increased serum fibroblast growth factor 2 levels, altered peripheral blood inflammatory indicators and their ratios in amyotrophic lateral sclerosis: a clinical exploratory study.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amyotrophic Lateral Sclerosis | Major topic |
| Fibroblast Growth Factor 2 | Major topic |
| Inflammation | Major topic |
| Humans | |
| Female | |
| Male | |
| Case-Control Studies | |
| Middle Aged | |
| Biomarkers | |
| Prospective Studies | |
| Aged | |
| Adult | |
| Disease Progression | |
| Neutrophils |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,370,540 | Characterizing the multiple roles of FGF-2 in SOD1G93A ALS mice in vivo and in vitro. | J Cell Physiol | 2019 | https://conductscience.org/library/papers/30370540 | PubMed |
| 2 | 38,829,511 | The Current Potential Pathogenesis of Amyotrophic Lateral Sclerosis. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/38829511 | PubMed |
| 3 | 38,355,415 | Serum fibroblast growth factor-2 levels complement vital biomarkers for diagnosing heart failure. | BMC Cardiovasc Disord | 2024 | https://conductscience.org/library/papers/38355415 | PubMed |
| 4 | 33,860,438 | Fibroblast Growth Factor Signalling in the Diseased Nervous System. | Mol Neurobiol | 2021 | https://conductscience.org/library/papers/33860438 | PubMed |
| 5 | 35,690,735 | Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis. | BMC Neurol | 2022 | https://conductscience.org/library/papers/35690735 | PubMed |
| 6 | 38,976,599 | Current potential diagnostic biomarkers of amyotrophic lateral sclerosis. | Rev Neurosci | 2024 | https://conductscience.org/library/papers/38976599 | PubMed |
| 7 | 40,908,696 | Precision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders. | Protein Pept Lett | 2025 | https://conductscience.org/library/papers/40908696 | PubMed |
| 8 | 40,689,333 | Unlocking amyotrophic lateral sclerosis: the role of adiponectin in inflammation and disease progression. | Front Neurol | 2025 | https://conductscience.org/library/papers/40689333 | PubMed |
| 9 | 33,924,474 | FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models. | Cells | 2021 | https://conductscience.org/library/papers/33924474 | PubMed |
| 10 | 40,109,661 | The systemic inflammation markers as potential predictors of disease progression and survival time in amyotrophic lateral sclerosis. | Front Neurosci | 2025 | https://conductscience.org/library/papers/40109661 | PubMed |
1 to 10 of 30
See all 30 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FGF2 | 2,247 | PubTator's text mining | https://conductscience.org/library/genes/2247 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42682425
GET https://conductscience.org/api/papers/v1/42682425/references?page=2